Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LDC000067 (LDC067)是一种高选择性CDK9抑制剂,IC50值为44±10 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 275 | 现货 | ||
5 mg | ¥ 470 | 现货 | ||
10 mg | ¥ 778 | 现货 | ||
25 mg | ¥ 1,590 | 现货 | ||
50 mg | ¥ 3,170 | 待询 | ||
100 mg | ¥ 4,560 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 858 | 现货 |
产品描述 | LDC000067 (LDC067) is a highly specific and selective CDK9 inhibitor with an IC50 value of 44±10 nM. |
靶点活性 | CDK9:44±10 nM |
体外活性 | LDC000067 reduces Ser2-P, induces p53 activation and leads to apoptosis in mESCs. In addition, LDC067 also dose-dependently inhibits P-TEFb-dependent de novo?RNA synthesis of cellular genes.[1] |
激酶实验 | The fluorescence resonance energy transfer (FRET)-based LANCE Ultra KinaSelect Ser/Thr kit is used to determine IC50 values for various CDK inhibitors. Briefly, a specific ULight MBP peptide substrate (50 nM final concentration) is phosphorylated by a CDK-cyclin pair in buffer (50 mM HEPES-KOH pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM dithiothreitol) containing ATP at the concentration of the Km values of the individual kinases for 1 h at room temperature. Subsequently, phosphorylation is detected by addition of specific Eu-labelled anti-phospho-antibodies (2 nM), which upon binding to the phosphopeptide give rise to a FRET signal. FRET signals are then recorded[1]. |
别名 | LDC067, (3-(6-(2-甲氧基苯基)嘧啶-4-基氨基)苯基)甲烷磺酰胺 |
分子量 | 370.43 |
分子式 | C18H18N4O3S |
CAS No. | 1073485-20-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 69 mg/mL (186.3 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6996 mL | 13.4978 mL | 26.9957 mL | 67.4891 mL |
5 mM | 0.5399 mL | 2.6996 mL | 5.3991 mL | 13.4978 mL | |
10 mM | 0.27 mL | 1.3498 mL | 2.6996 mL | 6.7489 mL | |
20 mM | 0.135 mL | 0.6749 mL | 1.3498 mL | 3.3745 mL | |
50 mM | 0.054 mL | 0.27 mL | 0.5399 mL | 1.3498 mL | |
100 mM | 0.027 mL | 0.135 mL | 0.27 mL | 0.6749 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
LDC000067 1073485-20-7 Apoptosis Cell Cycle/Checkpoint CDK LDC067 LDC 067 (3-(6-(2-甲氧基苯基)嘧啶-4-基氨基)苯基)甲烷磺酰胺 LDC-000067 Cyclin dependent kinase LDC 000067 inhibit Inhibitor LDC-067 inhibitor